McNeil Consumer to launch Nicotrol NS nicotine nasal spray in July.
Executive Summary
MCNEIL TO LAUNCH NICOTROL NS NICOTINE NASAL SPRAY IN JULY in conjunction with the Pathways to Change behavior modification program. Nicotrol NS prescription nicotine nasal spray (NDA 20-385) was approved by FDA on March 22 as an aid to smoking cessation. Under license from Pharmacia & Upjohn, the drug is indicated as an "aid to smoking cessation for the relief of nicotine withdrawal symptoms. Nicotrol NS therapy should be used as part of a comprehensive behavioral smoking cessation program," labeling states. Pharmacia filed an NDA for the nicotine nasal spray on July 30, 1993.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth